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Abstract
The response to an oral calcium load test was assessed in 17 hypercal-
ciuric nephrolithiasis patients who presented elevated parathyroid
hormone (PTH) irrespective of the ionized calcium (sCa2+) levels.
Blood samples were collected at baseline (0 min) and at 60 and 180
min after 1 g calcium load for serum PTH, total calcium, sCa2+, and
1.25(OH)2D3 determinations. According to the sCa2+ level at baseline,
patients were classified as normocalcemic (N = 9) or hypercalcemic
(N = 8). Six healthy subjects were also evaluated as controls. Bone
mineral density was reduced in 14/17 patients. In the normocalcemic
group, mean PTH levels at 0, 60 and 180 min (95 ± 76, 56 ± 40, 57 ±
45 pg/ml, respectively) did not differ from the hypercalcemic group
(130 ± 75, 68 ± 35, 80 ± 33 pg/ml) but were significantly higher
compared to healthy subjects despite a similar elevation in sCa2+ after
60 and 180 min vs baseline in all 3 groups. Mean total calcium and
1.25(OH)2D3 were similar in the 3 groups. Additionally, we observed
that 5 of 9 normocalcemic patients presented a significantly higher
concentration-time curve for serum PTH (AUC0',60',180') than the other
4 patients and the healthy subjects, suggesting a primary parathyroid
dysfunction. These data suggest that the individual response to an oral
calcium load test may be a valuable dynamic tool to disclose a subtle
primary hyperparathyroidism in patients with high PTH and fluctuat-
ing sCa2+ levels, avoiding repeated measurements of both parameters.
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Introduction
Primary hyperparathyroidism is charac-
terized by inappropriately increased secre-
tion of parathyroid hormone (PTH) in rela-
tion to the serum calcium level of the patient.
Clinically the disorder is accompanied by
hypercalcemia, serum levels of intact PTH
within or above the upper normal range and
an increased parathyroid cell mass (1).
The incidence of nephrolithiasis in pri-
mary hyperparathyroidism is 10 to 30% and
hypercalciuria is only present when the fil-
tered calcium load exceeds the maximum
ability of renal tubular reabsorption of cal-
cium induced by PTH (2,3). The increase of
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total serum calcium in hyperparathyroidism
is not always demonstrable and several meas-
urements may be needed to ensure that hy-
percalcemia is present. Although hypercal-
cemia is a key feature in establishing the
diagnosis of primary hyperparathyroidism,
the possibility of the existence of hyperpara-
thyroidism with intermittent or no elevation
in total serum calcium has been raised by
several investigators since the first descrip-
tion of normocalcemic hyperparathyroidism
in 1953 (4-8).
On the other hand, the suspicion of nor-
mocalcemic primary hyperparathyroidism
may be raised on the basis of a history of
recurrent renal calculi and increased urine
calcium excretion. Primary hyperparathyroid-
ism is observed in 1 to 5% of all calcium
stone formers (9). However, about 50% of
patients with renal calculi have idiopathic
hypercalciuria, a condition associated with
normocalcemia as determined by total se-
rum calcium. Despite initial evidence of sec-
ondary hyperparathyroidism due to chronic
renal tubular calcium leakage, many investi-
gators have not confirmed it (10-14).
It has been reported that the measure-
ment of ionized calcium is more sensitive
than total serum calcium to indicate hyper-
parathyroidism (5,15).
Levels of intact PTH even when deter-
mined by optimal two-site immunoassays
may reflect measurement of molecules with
no bioactivity (16). Thus, the overestimation
of PTH impairs the diagnosis of subtle pri-
mary hyperparathyroidism. In addition, there
is an intrinsic physiologic variation in serum
PTH levels. Therefore, several measurements
of both PTH and ionized calcium are needed
to diagnose parathyroid dysfunction in pa-
tients with intermittent or no elevation of
total serum calcium.
Although there are distinct pathophysi-
ologic mechanisms, failure to separate the
rare patient with normocalcemic primary
hyperparathyroidism from the idiopathic
hypercalciuria patients with eventual sec-
ondary hyperparathyroidism has led to inap-
propriate neck exploration (17).
We hypothesized that an oral calcium
load test could detect a dynamic response by
the parathyroid glands, providing better
evaluation of parathyroid dysfunction, rather
than multiple determinations of PTH and
ionized calcium.
Patients and Methods
Informed written consent to participate
was obtained from each patient and the study
was approved by the Ethics Committee of
Universidade Federal de São Paulo.
Seventeen outpatients (14 women and 3
men; mean age 48 ± 13 years) from the
Nephrology or Endocrinology Divisions pre-
senting high serum PTH levels irrespective
of total and ionized calcium levels, hypercal-
ciuria and or nephrolithiasis, were included
in the study.
Patients with chronic renal failure, endo-
crinological disorders such as hyperthyroid-
ism, acromegaly, sarcoidosis, diabetes mel-
litus, or neoplasias, or taking drugs which
could not be withdrawn during the protocol
(corticosteroid, diuretics, oral contraceptives,
etc.) were excluded. All patients were in-
structed by a dietitian to follow the same
dietary recommendations (i.e., calcium in-
take of 500 mg/day and sodium chloride
intake of 140 mEq/day) 2 weeks before the
test was performed. A control group matched
for calcium intake, consisting of 6 healthy
volunteers (4 women and 2 men; mean age:
26 ± 4 years) was studied.
Urinary calcium
A 24-h urine sample was obtained from 15
patients for calcium determination. Hypercal-
ciuria was defined as urinary calcium >250
mg/24 h for females, >300 mg/24 h for males
and/or ≥4 mg kg-1 24 h-1 for either sex (18).
Acute calcium load test. All patients and
controls were maintained on their regular
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diet before the test. Blood and urine samples
consecutively obtained during fasting and
after the oral calcium load were analyzed.
The patients started fasting soon after dinner
(19:00 h) during the evening preceding the
test except for 300 ml of distilled water
which they drank at 21:00 h and at midnight.
On the test day, the patients drank 300 ml of
distilled water at 6:00 h. At 7:00 h a blood
sample was drawn for measurements of total
and ionized calcium, intact PTH, creatinine,
1.25(OH)2D3, and phosphate. Basal urine
was collected over a period of 2 h from 7:00
to 9:00 h for calcium, creatinine and phos-
phate determinations. An oral calcium load
of 1 g (as gluconolactate and carbonate;
Calcium Sandoz F®, Basel, Switzerland) was
then given. The second period began imme-
diately after calcium administration. Another
blood sample was collected at 60 and 180
min following the calcium load for total and
ionized calcium, phosphate and intact PTH
determinations. Ionized calcium was drawn
under vacuum venipuncture and immedi-
ately centrifuged. In the second urine sample
collected 180 min after the calcium load,
calcium, creatinine and phosphate were again
determined.
Intact serum parathyroid hormone
Intact serum PTH was determined by an
in-house immunofluorometric assay (normal
range: 4-70 pg/ml) based on a chicken egg
yolk-derived amino-terminal antibody (PTH-
1-34) bound to a microtiter plate by anti-
chicken Ig monoclonal antibody. A Eu-
ropium-labeled carboxyl-terminal specific
monoclonal antibody produced from a mouse
immunized with a PTH-(53-84)-BSA conju-
gate was employed as the tracer antibody.
The intra-assay error was 5% and the inter-
assay error was 13.4% (19).
Ionized serum calcium
Ionized serum calcium was determined
by ion selective electrode (AVL Model 9180,
Roswell, GA, USA); normal range: ≤1.32
mmol/l. Total serum calcium was determined
by atomic absorption spectrophotometry
(Perkin-Elmer Atomic Spectrophotometer
290B, Norwalk, CT, USA); normal range:
8.5 to 10.5 mg/dl. Inorganic phosphate was
determined by the Fiske and Subbarow
method (20) and creatinine was measured by
the alkaline picrate Jaffe reaction (21).
1.25(OH)2D3 determination
Serum levels of 1.25(OH)2D3 were deter-
mined by radioimmunoassay (123I RIA kit;
DiaSorin, Stillwater, MN, USA); normal
range: 15.9 to 55.6 pg/ml.
Bone mineral density
Bone mineral density (BMD) was as-
sessed by dual-energy X-ray absorptiometry
at lumbar spine and femoral sites using a
DPX-L apparatus (Lunar Radiation Corp.,
Madison, WI, USA). The criterion for the
definition of osteopenia was a hip or spine
BMD value >1.0 SD below the mean BMD
for the young adult population (T score)
according to WHO criteria (22).
Parathyroid scintigraphy
The procedure was carried out using a
double-phase study with Tc-99 sestamibi
(APEX SPX, Haifa, Israel) (23).
Statistical analysis
Nonparametric tests were used. The
Mann-Whitney test was used for compari-
son between normocalcemic and hypercal-
cemic subjects and controls. The Wilcoxon
test was used to compare the results obtained
before and after the oral calcium load test in
the same group. Results are reported as mean
± SD and statistical significance was defined
as P < 0.05.
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Results
Patients’ characteristics on admission in-
cluding individual serum PTH, total and ion-
ized calcium values, urinary calcium, and T-
score are shown in Table 1. Hypercalciuria
was detected in 14 of 15 of the 24-h urine
samples obtained from all patients. Osteope-
nia was detected in 14/17 patients, but no
fractures were observed. Only 2 patients
(numbers 12 and 15) had hyperfunctioning
nodules identified by parathyroid scintigra-
phy (data not shown in Table 1).
Acute calcium load test
Patients were classified as normocalce-
mic (N = 9) or hypercalcemic (N = 8) accord-
ing to the level of ionized calcium deter-
mined at baseline (0 min). The normocalce-
mic group presented mean ionized calcium
similar to the control group at baseline (1.29
± 0.04 vs 1.30 ± 0.01 mmol/l) but signifi-
cantly lower than the hypercalcemic group
(1.29 ± 0.04 vs 1.39 ± 0.05 mmol/l). A
significant difference between the normo-
calcemic and hypercalcemic groups was also
observed at 60 (1.35 ± 0.05 vs 1.47 ± 0.10
mmol/l) and 180 min (1.39 ± 0.06 vs 1.51 ±
0.10 mmol/l) but the mean ionized calcium
of normocalcemic subjects remained similar
to control at 60 and 180 min. When com-
pared to baseline, all 3 groups presented
higher mean ionized calcium levels at 60 and
180 min after the load, as shown in Figure 1.
In contrast, mean total serum calcium was
similar among the normocalcemic, hyper-
calcemic and control groups at baseline (9.7
± 0.4 vs 9.7 ± 0.5 and 9.9 ± 0.4 mg/dl), at 60
min (10.0 ± 0.2 vs 10.4 ± 0.7 mg/dl and 10.1
± 0.5 mg/dl) and 180 min (10.3 ± 0.5 vs 10.3
± 0.7 and 10.3 ± 0.2 mg/dl), respectively.
As shown in Figure 2, the mean PTH of the
normocalcemic group was significantly higher
than control at baseline (95 ± 76 vs 30 ± 14 pg/
ml), after 60 min of calcium load (56 ± 40 vs 17
± 13 pg/ml) and also after 180 min (57 ± 45 vs
17 ± 11 pg/ml). However, mean PTH values
did not differ between the normocalcemic and
hypercalcemic groups at 0, 60 or 180 min (95
± 76 vs 130 ± 75, 56 ± 40 vs 68 ± 35 and 57 ±
45 vs 80 ± 33 pg/ml, respectively). There was
Table 1. Patient characteristics at admission.
Patients Gender Age PTH sCa Ca2+ uCa T-score
(F/M) (years) (pg/ml) (mg/dl) (mmol/l) (mg/24 h)
 L2-L4 Neck
1 F 29 135 9.8 1.17 350 -1.50 -0.03
2 F 50 74 8.7 1.33 262 0.29 -0.66
3 F 40 70 9.8 1.37 263 2.65 0.03
4 M 54 90 9.7 1.22 337 -0.81 -3.14
5 F 53 75 10.0 1.29 258 -2.00 -0.60
6 F 72 178 10.1 1.36 ND -1.55 0.06
7 M 36 70 9.8 1.36 395 -1.39 -0.81
8 M 29 70 9.0 1.37 374 -1.61 -1.49
9 F 48 93 9.6 1.23 302 -0.52 -1.90
10 F 42 74 10.2 1.29 284 0.45 0.97
11 F 54 105 10.3 1.31 308 -1.48 -0.19
12 F 77 168 10.6 1.32 145 -2.93 -4.26
13 F 26 70 10.2 1.37 283 0.57 -1.04
14 F 61 98 10.5 1.40 306 -2.43 -0.90
15 F 84 114 11.5 1.40 ND 0.18 -2.11
16 F 54 98 10.6 1.32 370 0.94 -3.20
17 F 47 140 11.1 1.42 270 -1.87 -1.99
Ca2+ = ionized serum calcium; F = female; M = male; PTH = parathyroid hormone; sCa = total serum calcium;
uCa = urinary calcium. ND = not determined.
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no difference among the normocalcemic, hy-
percalcemic and control groups in regard to
percent PTH suppression from baseline after
60 min (-40 ± 11, -46 ± 17 and -54 ± 20%,
respectively) or after 180 min (-40 ± 12, -38 ±
15 and -47 ± 30%).
The serum and urinary parameters ob-
tained during the calcium load test in the
normocalcemic group are presented in Table
2. The table shows that the mean PTH value
of patients 1, 3, 4, 6, and 7 was significantly
higher at 0 min and after 60 and 180 min,
respectively (134 ± 85, 81 ± 38 and 81 ± 57
pg/ml) when compared to that of patients 2,
5, 8, and 9 (46 ± 9, 25 ± 5 and 27 ± 5 pg/ml)
and of healthy subjects (30 ± 14, 17 ± 13 and
17 ± 11 pg/ml). The mean PTH value for
patients 2, 5, 8, and 9 did not differ from that
of the healthy subjects. The concentration-
time curve of serum PTH (AUC0',60',180') for
patients 1, 3, 4, 6, and 7 (16,171 ± 9005 pg
ml-1 min-1) was significantly higher than for
patients 2, 5, 8, and 9 (5280 ± 967 pg ml-1
min-1, P = 0.016) and also than the curve for
healthy subjects (3492 ± 202, P = 0.004). No
differences were found in mean urinary Ca/
Cr, or FeCa% between patients 1, 3, 4, and 7
and patients 2, 5, 8, and 9, as shown in Table 2.
The mean urinary Ca/Cr ratio (data not shown
Figure 1. Mean serum ionized
calcium levels (Ca2+) at base-
line (0 min) and at 60 and 180
min after oral calcium load in
hypercalcemic (squares), nor-
mocalcemic (circles) and con-
trol (triangles) subjects. *P <
0.05 vs hypercalcemic patients
(Mann-Whitney test).
Figure 2. Mean serum parathy-
roid hormone (PTH) levels at
baseline (0 min) and at 60 and
180 min after oral calcium load
in hypercalcemic (squares) nor-
mocalcemic (circles) and con-
trol (triangles) subjects. *P <
0.05 vs control subjects (Mann-
Whitney test).
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Table 2. Individual values of serum parathyroid hormone (PTH), 1.25(OH)2D3, urinary Ca/Cr ratio, and fractional excretion of calcium (FECa%)
during a calcium load test in normocalcemic patients.
Patients Ca2+ (mmol/l) PTH (pg/ml) 1.25(OH)2D3 Ca/Cr ratio FECa (%)
0 ' 6 0 ' 180' 0 ' 6 0 ' 180' 0 ' 0 ' 180' 0 ' 180'
2 1.27 1.33 1.40 40 26 25 42 0.11 0.18 1.0 20.6
5 1.31 1.48 1.50 38 18 22 74 0.35 0.36 2.7 36.3
8 1.31 1.36 1.43 48 29 27 41 0.11 0.22 1.0 21.5
9 1.32 1.36 1.37 59 28 34 21 0.20 0.22 1.9 19.6
X ± SD 1.30±0.1 1.38±0.1 1.43±0.1 46.0±9.0 25.0±5.0 27.0±5.0 45.0±21.0 0.19±0.1 0.24±0.1 1.7±0.8 24.5±7.9
1 1.17 1.26 1.26 279 142 159 32 0.32 0.38 3.3 37.5
3 1.30 1.33 1.41 93 50 33 35 0.14 0.24 1.1 24.6
4 1.31 1.34 1.38 72 56 43 59 0.14 0.22 1.3 22.2
6 1.31 1.36 1.39 146 97 99 64 0.18 0.37 1.4 37.3
7 1.31 1.35 1.36 82 60 70 42 0.11 0.23 1.0 22.6
X ± SD 1.28±0.1 1.33±0.1 1.36±0.1 134.0±85.0* 81.0±38.0* 81.0±57.0* 47.0±14.0 0.18±0.1 0.29±0.1 17±1.0 29.0±7.9
*P < 0.05 vs mean PTH of patients 2, 5, 8, and 9 (Mann-Whitney test).
1384
Braz J Med Biol Res 37(9) 2004
S.A. Gomes et al.
in tables) was significantly higher vs base-
line after 180 min in the normocalcemic
(0.27 ± 0.1 vs 0.18 ± 0.1), hypercalcemic
(0.43 ± 0.2 vs 0.19 ± 0.1) and control (0.24 ±
0.1 vs 0.11 ± 0.1) groups. Although the
hypercalcemic group tended to show a higher
urinary Ca/Cr value after 180 min in com-
parison to the other 2 groups, the difference
did not reach statistical significance.
Mean fractional calcium excretion was
significantly elevated after 180 min of oral
calcium load in the normocalcemic (27.0 ±
7.7 vs 1.7 ± 0.8%), hypercalcemic (44.0 ±
25.0 vs 1.6 ± 0.5%) and control (23.0 ± 0.11
vs 0.9 ± 0.1%) groups, but again did not
differ among the 3 groups.
Mean fractional phosphate excretion 180
min after the oral calcium load was only
significantly lower than baseline in the con-
trol group (3.3 ± 2.9 vs 9.8 ± 3.2%) but not in
the normocalcemic or hypercalcemic groups
(10.2 ± 5.3 vs 10.3 ± 6.3% and 10.5 ± 9.9 vs
12.7 ± 7.0%; data not shown in tables).
The mean values of 1.25(OH)2D3 also
did not differ between the normocalcemic,
hypercalcemic and control groups (46 ± 17
vs 48 ± 24 vs 36 ± 12 pg/ml). The individual
and mean values are presented in Figure 3.
Discussion
The diagnosis of classic primary hyper-
parathyroidism is easily established by in-
creased levels of PTH in the presence of
hypercalcemia. On the other hand, patients
with primary hyperparathyroidism may pres-
ent significant symptoms and minimal or no
elevation in total serum calcium levels (24).
Normocalcemic hyperparathyroidism de-
fined as completely normal total serum val-
ues is a rare entity that must be searched for
in patients with symptoms or complications
of hyperparathyroidism, such as renal cal-
culi and bone mineral loss (6). However, the
existence of normocalcemic hyperparathy-
roidism is still controversial (4-7). Another
possible explanation for the finding of high
levels of PTH with normal serum calcium
values is the putative secondary hyperpara-
thyroidism due to renal tubular leakage of
calcium in patients with idiopathic hypercal-
ciuria (10-12). Nevertheless, several investi-
gators have reported normal parathyroid func-
tion in idiopathic hypercalciuria (13,14,25).
Lundgren et al. (7) found abnormal para-
thyroid tissue (75% adenomas and 25% hy-
perplasias) in 16/57 (28%) postmenopausal
women with high PTH levels and normal
ionized and total serum calcium values, sug-
gesting the presence of normocalcemic pri-
mary hyperparathyroidism.
The reason why total serum calcium is
not increased in patients with primary hyper-
parathyroidism in the presence of normal
serum values of albumin, magnesium, phos-
phate, and 1.25(OH)2D3 is not clear. While
some investigators have attributed a normal
total calcium level in patients with normo-
calcemic hyperparathyroidism to an in-
creased ratio of ionized and ultrafiltrable
calcium to total calcium in these patients
compared to normal subjects, others did not
confirm it (15,26,27). Resistance to the ef-
fect of PTH in increasing renal tubular reab-
sorption of calcium resulting in higher uri-
nary calcium has also been postulated (28).
Another possibility could be the presence of
non-1-84 PTH circulating molecules such as
a 7-84 PTH fragment, blocking the calcemic
effect of 1-84 PTH and preventing hypercal-
cemia (16,29).
In the present study, we hypothesized
1.
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that an acute oral calcium load test would
help to better evaluate the dynamic response
of the parathyroid gland to fluctuations of
serum calcium in patients with high serum
PTH. The reproducibility of the test was
good since the test was easy to perform in an
outpatient setting (3 blood collections over a
period of 180 min), as already suggested by
other investigators (30,31), with a sensitivity
and specificity of 100 and 87% (31), respec-
tively. Calcium administration was well tol-
erated by all patients.
In response to the oral calcium load, ion-
ized calcium levels but not total serum cal-
cium levels were increased in normocalce-
mic, hypercalcemic and control patients. The
higher levels of ionized calcium were main-
tained even after 180 min in all 3 groups,
including the control. These data suggest
that ionized calcium is more sensitive than
total serum calcium in reflecting acute
changes in serum calcium regulation, as also
reported by others (5,15).
We observed a higher mean PTH in the
normocalcemic group compared to control
despite the similar elevation of ionized cal-
cium presented by both. The mean PTH in
this normocalcemic group was not signifi-
cantly different from that presented by the
hypercalcemic group, suggesting a distur-
bance in calcium set point in the former.
A significant difference in the percent-
age of mean PTH suppression from baseline
among the 3 groups was not evidenced in the
present study. These findings contrast with
those of Monchik et al. (30), who observed a
clear-cut separation between normal sub-
jects and patients with high PTH levels and
normal total serum calcium, whose PTH sup-
pression achieved values higher and lower
than 30%, respectively.
Although the mean percent PTH sup-
pression of the normocalcemic group did
not differ from control, we observed that
5 of 9 normocalcemic patients presented
a concentration-time curve of serum PTH
(AUC0',60',180') significantly higher not only
than control but also than the remaining 4
normocalcemic patients. It could be argued
that the minimal reduction of PTH in these 5
patients in response to the calcium load might
have reflected the detection of inactive long
half-life fragments of PTH. Nevertheless,
the different response among control pa-
tients using the same assay (19), which pre-
sents a good correlation (r = 0.938) with a
commercial immunoradiometric assay (PTH-
IRMA; Nichols Institute, San Juan Capis-
trano, CA, USA), does not suggest this hypo-
thesis. On the other hand, according to Sil-
verberg et al. (29), inactive 7-84 PTH frag-
ments may be produced by parathyroid ad-
enomas. It is important to emphasize that
although second-generation 1-84 PTH as-
says present a better diagnostic sensitivity in
primary hyperparathyroidism (16,29), they
are still not widely available and their diag-
nostic value is especially important among
patients with chronic renal failure.
Our findings suggested a disturbance in
calcium set point in the normocalcemic pa-
tients when compared to controls. It is note-
worthy that even the hypercalcemic group
was able to suppress PTH on a percent basis
as did the control group but, again, at levels
much higher than the normal range.
Recurrent stone formation was the main
clinical manifestation and hypercalciuria
could be detected in all but one of the normo-
calcemic patients (8/9).
In fact, hypercalciuria is found in classic
primary hyperparathyroidism only if the fil-
tered load of calcium exceeds the threshold
for renal tubular calcium reabsorption. Con-
sequently, urinary calcium should not be
elevated in normocalcemic hyperparathyroid-
ism patients, but rather in patients with idio-
pathic hypercalciuria because of the pres-
ence of the renal tubular reabsorption defect.
In our study, we observed that mean fasting
urinary calcium and urinary calcium after
calcium load corrected for creatinine excre-
tion and mean fractional calcium excretion
did not differ among the 3 groups.
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Following the oral calcium load, a reduc-
tion in fractional phosphate excretion was
observed only in the control group, reflect-
ing an appropriate PTH suppression in this
group. This finding emphasizes the lack of a
physiological response of phosphate reab-
sorption due to the persistent elevation of
PTH in both the normocalcemic and hyper-
calcemic groups.
In the present series, serum 1.25(OH)2D3
was similar among the 3 groups, in agree-
ment with Monchik et al. (30), who did
not observe an increased 1.25(OH)2D3 in
hyperparathyroidism patients. Conversely,
some investigators observed mild elevations
of 1.25(OH)2D3 levels in classic hyperpara-
thyroidism (9,32). Although the elevation
of 1.25(OH)2D3 in idiopathic hypercalciu-
ric patients has been reported by some
investigators, others have pointed out high
normal values or completely normal values,
so that this is still a matter of controversy
(32-34).
An elevated frequency of bone mass loss,
mainly cortical bone, is often found in pri-
mary hyperparathyroidism, as well as in nor-
mocalcemic calcium stone formers with
idiopathic hypercalciuria, mostly in trabecu-
lar bone (33,35). Some investigators have
hypothesized that a primary increase in bone
resorption due to a monocyte disorder may
result in hypercalciuria in these patients
(36,37). In our study, we observed osteope-
nia in 14 of 17 patients with similar distribu-
tion of affected sites, lumbar spine or femo-
ral neck.
Parathyroid scintigraphy was not helpful
in the diagnosis of hyperparathyroidism in
the present study, as also pointed out by
other investigators (38).
Although primary hyperparathyroidism
patients with the most marked elevation in
serum calcium levels are thought to present
the most marked symptoms, many investiga-
tors have reported that they may present
significant symptoms despite a minimal or
no elevation in their serum calcium level (4-
7,24). In a series of 142 patients with hyper-
calcemia, intermittent hypercalcemia or
normocalcemia, Siperstein et al. (24) ob-
served a similar frequency of preoperative
symptoms and surprisingly the same degree
of symptom amelioration after surgery, sug-
gesting that factors other than elevated se-
rum calcium levels are responsible for symp-
toms of hyperparathyroidism. These investi-
gators also did not find statistical differences
in the frequency of single adenomas, hyper-
plasia or multiple adenomas among these 3
subgroups.
This poses the problem of difficulties
regarding the diagnosis of hyperparathyroid-
ism, mainly if the patient is normocalcemic,
especially when one is dealing with ionized
calcium (39). As we could not easily estab-
lish the diagnosis of hyperparathyroidism in
these normocalcemic patients despite the
high PTH levels, we tested the dynamic re-
sponse of the parathyroid gland to an oral
calcium load. The response to the oral cal-
cium load test among normocalcemic pa-
tients showed heterogeneity with respect
to PTH levels, irrespective of the clinical
manifestation. The maintenance of higher
PTH levels, higher than the threshold of 31
pg/ml in 5 patients, differing statistically
from control, was probably due to an altered
calcium set point and suggests that a primary
dysfunction of the gland must be present.
The concentration-time curve of serum
PTH (AUC) of the remaining 4 patients was
slightly higher, although not significantly
different from control (5280 ± 967 vs 3492 ±
202). On the basis of this response, those 4
patients could be either considered as ad-
equate responders or as presenting second-
ary hyperparathyroidism. The use of thiaz-
ide drugs particularly in these patients in the
future might help us to further confirm such
hypothesis.
In conclusion, the present study suggests
that an oral calcium load test is a valuable
dynamic tool in identifying subtle primary
hyperparathyroidism in patients with elevated
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PTH and fluctuating ionized calcium levels,
avoiding numerous repeated PTH and serum
calcium determinations leading to inconclu-
sive results. The test also provides a faster
diagnosis determining an earlier therapeutic
intervention.
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